

Toray Out-Licenses Drug Candidate that Uses Novel Mechanism of Action to Treat Peripheral Neuropathy

Tokyo, Japan, November 26, 2025 – Toray Industries, Inc. and Sanodyne Therapeutics, Inc. announced today that they have entered into an exclusive worldwide license agreement granting Sanodyne the rights to develop, manufacture, and market TRK-750 (Toray code name), a drug candidate under development to treat peripheral neuropathy and neuropathic pain. Sanodyne will continue its R&D under the code name SNT-001.

Sanodyne will pay Toray upfront and milestone fees for each development stage, as well as sales-based milestone fees and royalties after the market launch.

Peripheral neuropathy is a condition characterized by dysfunction of one or more peripheral nerves, including motor nerves that control the movement of limbs, sensory nerves that transmit sensations, and autonomic nerves that regulate the functions of internal organs. This ailment can result from such conditions as shingles, diabetes, or chemotherapy. Reported symptoms include burning pain and tingling sensations (neuropathic pain), numbness, paralysis, and muscle weakness. At least 200 million people worldwide suffer from this condition (see note 1). While certain drugs can relieve some symptoms, treatment needs remain largely unmet, as peripheral neuropathy arises from diverse underlying causes.

Nonclinical studies have demonstrated that SNT-001, small molecule compound with a novel mechanism of action (note 2) suppresses neuropathic pain and helps protect peripheral nerves from damage and promote their repair. A Phase I clinical trial in the United Kingdom demonstrated favorable tolerability and safety with no serious central nervous system adverse events. Sanodyne plans to initiate a Phase II clinical trial in 2026.

Toray, pursuing an open innovation strategy that concentrates on areas leveraging its key proprietary drug discovery technologies, will collaborate extensively with external entities by licensing out or jointly developing candidate compounds that it identifies through its research. The company will further accelerate drug innovation with venture firms and pharmas.

Sanodyne, alongside developing SNT-001, will introduce, research, and develop new therapies for neuropathy and pain.

Together, Toray and Sanodyne will accelerate clinical development and commercialization, aiming to deliver effective treatments to patients suffering from peripheral neuropathy and neuropathic pain.

Notes

1. Claudia Hammi, Brent Yeung. Neuropathy. StatPearls[Internet] Treasure Island (FL). StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542220/>, (2025-10-02).
2. Mechanism of action refers to the process by which a drug produces its therapeutic effects in the body. It describes biological reactions when drugs interact with target molecules to achieve desired therapeutic outcomes.
3. Adverse central nervous system events are undesirable or unintended signs, symptoms, or disorders resulting from a drug's effects on the central nervous system. These include abnormalities in clinical laboratory values, regardless of whether there is a causal relationship with the drug. Depending on their severity, such events may significantly affect quality of life and treatment continuity.

Corporate Profiles

Toray Industries, Inc.

Headquarters: Nihonbashi-Muromachi 2-chome 1-1, Chuo-ku, Tokyo

Establishment: April 1926

Representative: Mitsuo Ohya, president and representative director

Principal businesses: Toray harnesses its core technologies in organic synthetic chemistry, polymer chemistry, biotechnology, and nanotechnology to create advanced materials for diverse fields. These include Fibers & Textiles, to Resins & Chemicals, Films, Electronics & Information Materials, Carbon Fiber Composite Materials, Pharmaceuticals & Medical Products, as well as Water Treatment & Environment.

Website: <https://www.toray.com/>

Sanodyne Therapeutics, Inc.,

Headquarters: Muromachi Nihonbashi 3-chome 2-1, Chuo-ku, Tokyo

Establishment: April 2025

Representative: Kazuhiko Nonomura Ph.D., representative director

Overview: This drug discovery startup was established under the leadership of two Japanese venture capital firms with a mission to bring hope and relief to patients suffering from peripheral neuropathy and other forms of neuropathic pain.

Website: <https://sanodyne.com/>

For more information, please visit our website at www.sanodyne.com.